You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 24, 2015

Front-of-Package Labeling in Thailand

Informed Counsel

Expanding waistlines and increasing health awareness have given rise to a consumer culture infatuated with well-being, not only in Thailand but all over the world. For producers, this means intense pressure to create healthy or healthier versions of their products. For the government—specifically the Thai Food and Drug Administration (FDA)—this means an obligation to implement and enforce stricter regulations on food and nutrition.

The Thai Perspective

As we move into an age where life is increasingly fast-paced, there is no reason why the food industry should be left behind. While nutritional labels are often displayed on the back of packaging, Front-of-Package (FOP) labeling has become popular among policy makers because it simplifies the most important information and places it where it is visible at first sight to the hurried consumer. In Thailand, the original 1998 Notification of the Ministry of Public Health (MOPH) implemented non-FOP nutritional labeling requirements which were mandatory for certain foods and voluntary for others. A survey conducted in 2009, however, concluded that the nutritional information was difficult to understand, which caused the FDA to make a number of changes.

In a series of subsequent ministerial notifications, the FDA implemented the Guideline Daily Amount (GDA) system of labeling, an FOP system that made GDA labels mandatory for snack products and certain ready-to-eat foods. The current GDA label breaks down nutritional information into four categories: calories, sugars, fats, and sodium. This requires producers to clearly state the nutrient content and percentage of recommended daily intake per package.

FOP Labeling Around the World

Countries around the world have also introduced policies which mirror the objectives of the GDA system of labeling to help consumers make the “smart” choice quickly. For example, the European Union takes the same approach as Thailand, basing its guidelines on the latest published scientific data on dietary requirements and recommendations. Similarly, the United States uses a voluntary Facts Up Front labeling system, which calls for a summary of calories, saturated fat, sodium, and sugar per serving on the front of various food and beverage products.

Singapore, on the other hand, uses the Healthier Choice Symbol, an interpretive nutrition logo which distinguishes products that are lower in saturated fat and trans fat, sodium, and sugar, but higher in whole grains, fiber, and other healthy nutrients. Nutrition guidelines are set according to each product category. There are 12 main product categories and more than 70 subcategories. In addition, there are variants including the Healthier Snack Symbol and the Healthier Ingredient Symbol.

Australia and New Zealand use the Daily Intake Guide and the Health Star Rating. The Daily Intake Guide is a voluntary scheme which uses a set of reference values for acceptable levels of intake for energy and a variety of nutrients, sugars, protein, fat, fiber, and sodium, to name a few. The Health Star Rating system was developed to make it easier for consumers to compare similarly packaged food and therefore make healthier decisions. It ranks products on a scale from half a star to five stars based on their nutritional profile which includes, for example, energy, saturated fat, and sodium. This system of labeling is a hybrid of the GDA system used by Thailand, the European Union, and the United States, as well as the Healthier Choice Symbol used by Singapore.

The Future of FOP Labeling

The food and beverage community has pushed to revamp the current FOP labeling scheme in Thailand. Currently, the National Food Committee, a subcommittee of the Thai FDA, is working to add to the present FOP GDA labeling scheme, but the additions have yet to be announced. It is known, however, that use of the new FOP label will be voluntary and presently it is only being considered for certain foods. Some organizations are looking for inspiration in the “traffic light” nutritional labeling system, a system that uses the colors red, amber, and green to indicate high, acceptable, and low levels of fat, saturated fats, sugar, and salt in various products. Foods with “green” indicators are healthier than foods with “red” indicators, while foods with “amber” indicators fall in between.

The Federation of Thai Industries Food Group has supported the use of GDA nutrition labels and is determined to become involved in educating consumers about the GDA system of labeling. It prefers the GDA system of labeling to a color-coded system or an interpretive nutritional logo because these are sometimes misleading and vague and often do not comprehensively take into account different nutritional needs.

The good news is that the industry has been invited to participate in the development of a new scheme which producers can both contribute to and benefit from. With the correct industry input, FOP labeling should offer consumers informative nutritional information that is apt for a fast-paced world.

RELATED INSIGHTS​ 

May 27, 2025
On May 16, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 12/2025/TT-BYT on registration of drugs and drug materials (Circular 12). Circular 12 will come into effect on July 1, 2025, replacing Circular No. 08/2022/TT-BYT (as amended), which provides the current regulations on drug registration, along with Circular No. 16/2023/TT-BYT on registration of drugs under toll manufacturing and technology transfer, and Circular No. 07/2017/TT promulgating the list of non-prescription drugs. Some of the key stipulations of Circular 12 are outlined below. Regulation of non-prescription drugs Circular 12 abolishes the detailed list of over-the-counter (OTC) drugs previously stipulated in Circular No. 07/2017/TT-BYT. Instead of relying on a fixed list for classification, Circular 12 introduces a new framework based on principles, criteria, and specific methods for determining the status of non-prescription/OTC drugs. This approach aims to enhance safety, ensure timely access, reflect actual usage and supply conditions, and align with international standards. Drugs that have already been approved will retain their classification (i.e., as prescription or non-prescription) throughout the validity of their marketing authorization (MA), and reclassification will be considered when the MA is renewed. If a change in classification is requested, the MA holder must submit a variation registration dossier to the Drug Administration of Vietnam (DAV). For drug registration dossiers currently under evaluation by the DAV, the classification will be assessed in accordance with the new provisions set out in Circular 12. Drug registration The new regulations under Circular 12 loosen the requirements on providing a Certificate of Pharmaceutical Product (CPP). For all drug registration cases, a single CPP will suffice, provided it is issued by the competent authority of the manufacturing country or by an authority from a country that is a member of the European Medicines Agency (EMA) or a Stringent Regulatory Authority (SRA), and confirms
May 15, 2025
Vietnam’s Ministry of Health (MOH) has published for public consultation a draft amendment of the Law on Donation, Recovery, and Transplantation of Human Tissues and Organs and Donation and Retrieval of Cadavers, a law which has been in effect since 2007. Among its changes, the draft amendment notably includes new provisions on stem cells, a hot-button topic with social, legal, and ethical ramifications extending beyond the medical field. There are currently no specific regulations on stem cells under Vietnamese law—only the MOH’s technical guidance—leaving many controversial issues unsettled. Key points related to stem cells that may impact the activities of researchers and institutions in Vietnam and abroad are highlighted below. Requirements for Stem Cells Under the draft amendment, stem cells are defined as cells naturally occurring in the body, having the ability to divide and differentiate into various types of cells. The draft amendment outlines conditions for stem cell donation, establishes requirements for medical facilities authorized to receive stem cell donations, and specifies the rights of stem cell donors. Under the draft amendment, it is prohibited to receive, screen, or produce stem cells at facilities that do not satisfy conditions. Establishment of Private Stem Cell Banks In addition to state-owned stem cell banks, the draft amendment also addresses independent stem cell banks established by private investors. In general, the stem cell banks (whether public or private) must obtain an operation license by meeting various conditions on personnel, equipment, facilities, and management systems to be further guided by the government. Notably, stem cell banks will have the right to cooperate with foreign entities in exchanging stem cells for treatment, education, and research purposes. Prohibition on Creating Embryos for Stem Cell Research or Therapy Considering the ethical concerns over the use and destruction of embryos, the draft amendment expressly prohibits the
May 2, 2025
Attorneys from Tilleke & Gibbins have updated the latest edition of Doing Business in Thailand, a Q&A-style guide from Thomson Reuters Practical Law that offers an overview of key legal considerations for companies operating in jurisdictions worldwide. The contribution outlines the country’s legal and regulatory framework for foreign investment and business operations and reflects the latest legislative developments. The chapter addresses the following core topics: Legal system: Structure of the courts and the codified nature of Thai law. Foreign investment: Business restrictions under the Foreign Business Act, sector-specific regulations, exchange control rules, and investment incentives. Business vehicles: Overview of partnerships, private and public limited companies, and other legal entities. Employment: Labor protections, employment contracts, foreign worker requirements, and termination procedures. Tax: Corporate and personal income tax, indirect taxes, and tax obligations for residents and non-residents. Intellectual property: Registration and enforcement of patents, trademarks, designs, and copyrights. Data protection: Key provisions of the Personal Data Protection Act and related compliance obligations. Competition law: Regulatory framework under the Trade Competition Act. Anti-bribery and corruption: Relevant legislation and enforcement mechanisms. E-commerce and digital business: Legal regime for online transactions and digital platforms. Marketing and advertising: Consumer protection laws and regulations affecting advertising and marketing practices. Product regulation and liability: Safety standards, liability regimes, and roles of enforcement authorities. Practical Law, a legal reference resource from Thomson Reuters, publishes a range of guides for hundreds of jurisdictions and practice areas. The insurance and reinsurance guide is a valuable resource for legal practitioners, covering numerous jurisdictions worldwide. To view the latest version of the guide, please visit the Practical Law website and enroll in the free Practical Law trial to gain full access.
March 7, 2025
On November 22, 2024, the Ministry of Health (MOH) in Laos issued Decision No. 3730/MOH, which regulates the management, processing, production, and use of biopharmaceutical products, genes, and stem cells. This decision came into force on January 18, 2025, 45 days after its publication in the Lao Official Gazette on December 4, 2024. This decision signifies Laos’ recognition and acceptance of biopharmaceutical products, genes, and stem cells for use in medical treatments and the beauty industry, and it aligns with the ongoing development of biomedical sciences in the country. Definitions The MOH’s decision defines biopharmaceuticals, gene therapy, and stem cells as follows: “Biopharmaceutical products” refers to a type of biological or drug product that is produced or synthesized from natural substances, objects, or chemicals. This group of products includes blood, blood components, allergens, cells or cellular components, gene therapies, tissues, protein-based medicines, drugs derived from living cells, and biologics, which can be produced from sugars, proteins, amino acids, or substances with complex characteristics derived from organic sources such as human, animal, and plant parts; yeast; and microorganisms. These products exclude vaccines and biosimilar products, which will be specified under separate regulations. “Gene therapy” refers to a treatment approach that applies the principle of arranging amino acids (which could involve DNA or RNA sent to the patient’s cells in the form of a drug with the purpose of treating a certain disease). “Stem cells” are defined in the decision as cells or immature cells that can be sourced from various organs in the They are characterized by being undifferentiated, having the potential for differentiation, and being self-renewing. Stem Cell Production The decision outlines comprehensive provisions for managing and using raw materials in stem cell production. Key points include: Production location standards: Ensuring facilities meet specific standards of the MOH. Personnel